Journal: Translational Oncology
Article Title: LMO2 confers value as a potential immunotherapy marker in pan-cancer analysis and inhibits progression of Clear Cell Renal Cell Carcinoma
doi: 10.1016/j.tranon.2025.102409
Figure Lengend Snippet: LMO2 may regulate NFKB pathway via Bex1 in ccRCC. A. Heatmap of differentially expressed genes in RNA sequencing data with LMO2 overexpression; B. GO, BP and MF analysis based on data in A; C. The enrichment of KEGG pathway implies that TNF-NFKB pathway is responsible for LMO2 regulation; D. The p-p65 expression in LMO2 expression and control in 786-O and ACHN; E. Statistical analysis of OD value in D; F. The ELISA assay results of nuclear p-p65 concentration in LMO2 expression and control in 786-O and ACHN; G. String database indicates the possible interacting genes of LMO2. Organisms column was restricted to Homo sapiens; H. Gene Mania indicates the possible interacting genes; I. The BEX1 expression in ccRCC from TCGA database; J. The correlation analysis of BEX1 and LMO2 in ccRCC from the database TCGA. * P < 0.05, ⁎⁎ P < 0.01, ⁎⁎⁎ P < 0.001.
Article Snippet: NF-κB p65 activation was measured by a TransAM NF-κB p65 kit (Active Motif, USA).
Techniques: RNA Sequencing, Over Expression, Expressing, Control, Enzyme-linked Immunosorbent Assay, Concentration Assay